Drug Trial Radar · NCT07738510
A Study to Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Oct 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Halia Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Jul 31, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to two part. First, dose selection for dose optimization based on safety of ofirnoflast. Second, to evaluate the efficacy of ofirnoflast administered in the study population. The secondary objectives of this study are to evaluate the extended hematologic response to ofirnoflast, to assess the safety and tolerability of ofirnoflast during dose optimization, and to evaluate hematologic improvement with ofirnoflast treatment.
Conditions
- Myelodysplastic Syndromes
- Anemia
Interventions
OfirnoflastDrug
tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose selection for dose optimizationTime frame: Days 1-28 of each Part 1 Cohort
- Evaluate the efficacy of ofirnoflast in to low- to intermediate-risk MDS who are transfusion dependentTime frame: Weeks 1-24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cleveland Clinic
Cleveland, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.